#Ziagen

An HIV-specific model underestimated the risk for heart attacks and other cardiovascular events.

A recent study randomized those with a moderate long-term risk of heart attack to receive Crestor (rosuvastatin) or a placebo.

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.

A large, ongoing study of people with HIV found that only a couple of older antiretrovirals were linked to high blood pressure.

Most of such drug resistance seen is to older drugs.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Ziagen is included in the combination-tablet regimens Triumeq and Trizivir and the two-drug combo tablet Epzicom.

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

Every decade spent living with HIV is equivalent to an additional 10 years of ordinary aging’s contribution to heart attack risk.

Various HIV antiretrovirals are linked to a raised risk of cardiovascular problems, although the overall risk of such an outcome is still low.

Multi-antiretroviral combination tablets appear to combat HIV no better than regimens that include individual tablets.

A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...

There is an apparent link between taking Viread (tenofovir) and developing kidney damage among HIV-positive people with low body weight.

A majority of people taking antiretrovirals to treat HIV could switch to newer regimens with improved side effect profiles.